(redirected from Epoetin)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to erythropoietin

a glycoprotein secreted by the kidneys that stimulates the production of red blood cells

Related Words

References in periodicals archive ?
Efficiency of NeoRecormon(R) - less product needed to achieve a clinically significant 1g/dl increase in Hb: Patients received a mean cumulative dose of 201,428 IU NeoRecormon(R), 208,823 IU darbepoetin alfa(6) and 284,722 IU epoetin alfa.
4 /PRNewswire/ -- An updated analysis from a 2001 study conducted by the Gynecologic Oncology Group evaluating Epoetin alfa in 109 patients with cervical cancer has been posted online (http://dx.
Recent studies have demonstrated that epoetin alfa is more cost-effective, and considerably less expensive, than darbepoetin[10] due to earlier and higher Hb response rates.
Poster: Treatment of MDS Related Transfusion-Dependent Anemia With Epoetin alfa: A Meta-Analysis Perspective Suneel Mundle, Ph.
As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.
Seven major markets - biosimilar epoetin alpha forecast 46
NYSE: HSP), a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, presented two studies that support an evaluation of biosimilarity of its proposed biosimilar, Epoetin Hospira, with the U.
Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs.
To test these hypotheses, we examined the mediational effect of three injectable medications, IV epoetin, IV iron, and IV vitamin D, in relation to facility organizational status and patient mortality.
But in the two Y studies of patients on dialysis, panelists agreed that the safety and efficacy of peginesatide were comparable with epoetin and cited the convenience of once-a-month dosing for patients.
Erythropoietic-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa are frequently used for the treatment of anemia of chronic kidney disease (CKD) (KDOQI, 2006; Moist, 2008).
once monthly as a single intravenous or subcutaneous injection to maintain target haemoglobin levels for patients currently being treated with an ESA (epoetin alfa, epoetin beta and darbepoetin alfa) who are converted to treatment with MIRCERA.
Trials have demonstrated that injecting epoetin alfa, a form of erythropoietin, improves brain function and quality of life in these people.